2 completed, 1 active not recruiting, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Priyanka Sharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HER2-positive Breast Cancer Registry HER2 + Breast Cancer | Recruiting | Priyanka Sharma | 1000 | 2024-09-27 | 2026-07-17 | |
| Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Romidepsin, Cisplatin, Nivolumab - Triple-Negative Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Priyanka Sharma | 51 | 2015-07-17 | 2025-10-06 |
| Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer Paclitaxel, Carboplatin, Doxorubicin - Triple-negative Breast Cancer | Phase 2 | Completed | Priyanka Sharma | 101 | 2015-07-01 | 2021-05-10 |
| BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer BYL-719 (alpelisib), Nab-paclitaxel - Breast Cancer | Phase 1 / Phase 2 | Completed | Priyanka Sharma | 43 | 2015-02-01 | 2022-06-07 |
Breast Neoplasms (4) · Triple Negative Breast Neoplasms (2)
130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Histone Deacetylase Inhibitors (1) · Nivolumab (1) · Paclitaxel (1) · romidepsin (1)
United States (4)